Clinical trials: Cutaneous Lupus
Cutaneous Lupus Erythematosus
Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants
The goal of this study is to investigate the safety and tolerability of the topical application of SOF-SKN in healthy volunteers. The study will be divided into part 1 and part 2.
- Trial name
- HERACLES (NCT07072611)
- Testing
- SOF-SKN 0.25%, SOF-SKN 0.5%, SOF-SKN 1%
- Where
- Australia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Noxopharm Limited
Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus
Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
The primary purpose of the study is to evaluate the efficacy of BIIB059 (litifilimab) in reducing disease activity in participants with systemic lupus erythematosus (SLE) with active cutaneous manifestations and joint involvement…
- Trial name
- LILAC (NCT02847598)
- Testing
- BIIB059 (litifilimab)
- Where
- 128 sites in United States, Argentina and 10 more
- Volunteers
- 264 people
- Sponsor
- Biogen
Discoid Lupus Erythematosus (DLE)
The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus
A 20 week study to assess the safety and efficacy of etanercept(Enbrel®)for the treatment of Discoid Lupus Erythematosus
- Trial name
- DISCLUP2008 (NCT00797784)
- Testing
- etanercept(Enbrel®)
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Florida Academic Dermatology Centers
Cutaneous Lupus Erythematosus
IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus
The purpose of this research study is to show that non-steroidal treatment with intravenous immunoglobulin (IVIg) can replace current systemic immunosuppressive therapy in cutaneous lupus erythematosis (CLE) patients.
- Trial name
- NCT01841619
- Testing
- IVIg
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of California, Irvine
Lupus Nephritis
Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis
The overall purpose of the study is to assess the efficacy of three different doses of BI 655064 against placebo as add-on therapy to standard of care (SOC) treatment for active lupus nephritis in order to characterize the…
- Trial name
- NCT02770170
- Testing
- BI 655064 dose 1, BI 655064 dose 2, BI 655064 dose 3
- Where
- 74 sites in United States, Australia and 18 more
- Volunteers
- 121 people
- Sponsor
- Boehringer Ingelheim
Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
The goal of this clinical trial is to learn if VENT-03 works to treat patients with cutaneous lupus erythematosus (CLE) who may or may not have systemic lupus erythematosus (SLE).
- Conditions
- Cutaneous Lupus Erythematosus (CLE), Systemic Lupus Erythematosus, SLE, SLE (Systemic Lupus)
- Trial name
- AERIS (NCT07260877)
- Testing
- VENT-03
- Where
- 34 sites in United States, Bulgaria and 6 more
- Volunteers
- 24 people
- Sponsor
- Ventus Therapeutics U.S., Inc.
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers
The purpose of this study is to obtain skin, blood, and urine samples from patients with active cutaneous lupus lesions and from healthy participants.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy
- Trial name
- NCT02034344
- Testing
- Skin biopsy, Blood collection, Urine collection
- Where
- 21 sites in United States, Germany and 4 more
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Cutaneous Lupus
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
This is a single-arm, multi-site, proof-of-concept study that will evaluate the treatment of 10 participants with cutaneous lupus erythematosus (CLE) with Tofacitinib.
- Trial name
- NCT05048238
- Testing
- Tofacitinib
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cutaneous Lupus Erythematosus
Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus
Primary Objective: Assess the efficacy of SAR443122 in cutaneous lupus erythematosus (CLE) Secondary Objectives: Assess the effect of SAR443122 on the physician's global assessment of disease activity (PhysGA - disease activity)…
- Trial name
- CLEan (NCT04781816)
- Testing
- SAR443122
- Where
- 50 sites in United States, Argentina and 13 more
- Volunteers
- 78 people
- Sponsor
- Sanofi
Discoid Lupus Erythematosus
Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients
The purpose of this study is to determine the clinical and immunological effects of the phosphodiesterase type 4 inhibitor, CC-10004, on skin inflammation associated with cutaneous lupus erythematosus.
- Trial name
- NCT00708916
- Testing
- CC-10004
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- NYU Langone Health
Cutaneous Lupus Erythematosus
Low-dose UVA1 Radiation in Cutaneous Lupus Patients
The investigators are conducting an open-label clinical trial determining the effects of UVA1 phototherapy on cutaneous lupus (CLE) patients.
- Trial name
- NCT01776190
- Testing
- UVA1 radiation treatment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ben Chong
Lupus Erythematosus, Cutaneous
Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars
Cutaneous Lupus erythematosus (CLE) is a chronic autoimmune connective tissue disease with a prevalence of 14.6 - 73.2/100,000, predominantly in women in mid adulthood.
- Trial name
- NCT04707924
- Testing
- Er:YAG laser
- Where
- Switzerland
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Discoid Lupus Erythematosus
A Multicentre, Randomised, Double-blind, Positive-control Clinical Trial Evaluating Dihydroartemisinin Tablets for the Treatment of Discoid Lupus Erythematosus
This study is a multicentre, randomised, double-blind, double-dummy, phase II clinical trial with a positive-control group, designed to evaluate the efficacy and safety of dihydroartemisinin tablets in the treatment of discoid…
- Trial name
- NCT07557927
- Testing
- Dihydroartemisinin tablets, Hydroxychloroquine tablets
- Where
- 10 sites in China
- Volunteers
- 100 people
- Sponsor
- Kunming Pharmaceuticals, Inc.
Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus
Study of M5049 in CLE and SLE Participants
This study is to evaluate the safety, tolerability and pharmacokinetics (PK) of orally administered M5049 in participants with systemic lupus erythematosus (SLE) or cutaneous lupus erythematosus (CLE).
- Trial name
- NCT04647708
- Testing
- M5049
- Where
- 12 sites in Bulgaria, Germany and 4 more
- Volunteers
- 25 people
- Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
SLE (Systemic Lupus), Lupus Erythematosus, Systemic
A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus…
- Conditions
- SLE (Systemic Lupus), Lupus Erythematosus, Systemic, Lupus Nephritis, Systemic Sclerosis
- Trial name
- NCT06925542
- Testing
- CTX112
- Where
- 17 sites in United States, Germany and 1 more
- Volunteers
- 80 people
- Sponsor
- CRISPR Therapeutics
Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus Rash
Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus
This clinical study will test the efficacy and safety of nicotinamide for lupus-associated skin lesions refractory to the treatment of hydroxychloroquine plus low-dose corticosteroids in patients with cutaneous lupus…
- Trial name
- NCT03260166
- Testing
- nicotinamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Xiangya Hospital of Central South University
Cutaneous Lupus Erythematosus(CLE)
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
A Study on the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Dose of SHR-7012 in Healthy Adults
- Trial name
- NCT07749651
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Cutaneous Lupus Erythematosus
Deep Phenotyping of Cutaneous Lupus Erythematosus
Cutaneous lupus erythematosus (CLE) is an autoimmune disease of which the pathogenesis and pathophysiology are not fully understood.
- Trial name
- NCT06411106
- Testing
- IMIQUIMOD cream 50mg/g
- Where
- Netherlands
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Centre for Human Drug Research, Netherlands
Systemic Sclerosis Cutaneous Lupus E Myopathies Systemic Lupus Erythematosus
Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment
The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator…
- Trial name
- ROSY-S (NCT07691970)
- Testing
- Anifrolumab
- Where
- 153 sites in United States, Argentina and 33 more
- Volunteers
- 1,072 people
- Sponsor
- AstraZeneca
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
In this study, researchers will learn more about a study drug called litifilimab (BIIB059) in participants with cutaneous lupus erythematosus (CLE).
- Trial name
- AMETHYST (NCT05531565)
- Testing
- Litifilimab
- Where
- 315 sites in United States, Argentina and 28 more
- Volunteers
- 450 people
- Sponsor
- Biogen